Boehringer Ingelheim GmbH And AbGenomics Corporation Sign Worldwide Exclusive Collaboration And License Agreement To develop And Commercialize A Therapeutic Monoclonal Antibody
10/19/2005 5:09:20 PM
Ingelheim/Germany and Taipei/Taiwan, 6 June 2005 - Boehringer Ingelheim International GmbH and AbGenomics Corporation announced today that they have signed an exclusive licensing agreement providing Boehringer Ingelheim with the worldwide exclusive rights to develop, manufacture and commercialize any products with AbGenomics Corporation’s antibody 168. Based on data generated by AbGenomics Corporation, antibody 168 may potentially be developed to treat a broad range of immune-related diseases. The initial focus of the development will be on therapies for autoimmune diseases. Specific terms of the transaction were not disclosed but they are comparable to the average licensing deals for compound of a similar stage and market potential. Also, AbGenomics Corporation has an option to co-promote in selected Asian countries.
“Monoclonal antibodies are an increasingly important component of medical treatments. AbGenomics Corporation’s antibody 168, with its novel mechanism of action, has the potential of introducing a new therapeutic paradigm for the treatment of autoimmune diseases. Our agreement with AbGenomics Corporation is the latest example of our corporate strategy to build long-term growth by focusing on biopharmaceuticals and on potential disease areas with unmet medical needs.” said Dr Andreas Barner Vice Chairman of the Board Corporate Division Pharma Research, Development and Medicine at Boehringer Ingelheim.
comments powered by